Cardiac arrest & resuscitation
Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Pooled result · All-cause mortalityResult — go to the resultRelative risk 0.90 95% CI 0.82–0.98Authors' conclusion
IV cangrelor was associated with reduced mortality following PCI in hemodynamically unstable patients, with the most pronounced benefit observed in those with CS, alongside improved coronary flow.
Study context
- Population
- Critically ill patients with cardiogenic shock (CS) or post-cardiac arrest (CA) undergoing percutaneous coronary intervention (PCI)
- Participants
- 4,537 patients · 12 studies
- Comparison
- Adjunctive intravenous (IV) cangrelor vs oral P2Y12 inhibitor during PCI
- Outcome
- All-cause mortality
Pooled result
As reported in the abstract
Relative risk
0.90
95% CI 0.82–0.98
Cangrelor vs Oral P2Y12 inhibitor
RR 0.90 (95% CI 0.82–0.98)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| All-cause mortality, CS (subgroup)Significant | 0.86 (0.78–0.96) | |
| All-cause mortality, CA (subgroup) | 0.94 (0.74–1.18) | |
| Post-PCI TIMI 3 flowHigher rates with cangrelor | 1.14 (1.01–1.29) | |
| 0.512Relative risk (log scale) |
Cardiovascular (CV) mortality
- No significant difference: RR
- 0.96 (95% CI, 0.76-1.22)
Stent thrombosis
- No significant difference: RR
- 0.72 (95% CI, 0.34-1.53)
Myocardial infarction (MI)
- No significant difference: RR
- 0.83 (95% CI, 0.44-1.57)
Stroke
- No significant difference: RR
- 1.83 (95% CI, 0.89-3.74)
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Major bleedingNot significantly increased overall | 1.37 (0.95–1.97) | |
| Major bleeding (controlled studies) | 1.50 (1.10–2.05) | |
| 0.512Relative risk (log scale) |
Original publication
Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Crit Care. Published 28 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →